Combinatorial CRISPR-Cas9 Metabolic Screens Reveal Critical Redox Control Points Dependent on the KEAP1-NRF2 Regulatory Axis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Summary The metabolic pathways fueling tumor growth have been well characterized, but the specific impact of transforming events on network topology and enzyme essentiality remains poorly understood. To this end, we performed combinatorial CRISPR-Cas9 screens on a set of 51 carbohydrate metabolism genes that represent glycolysis and the pentose phosphate pathway. This high-throughput methodology enabled systems-level interrogation of metabolic gene dispensability, interactions, and compensation across multiple cell types. The metabolic impact of specific combinatorial knockouts were validated using 13C and 2H isotope tracing, and, these assays together revealed key nodes controlling redox homeostasis along the KEAP1-NRF2 signaling axis. Specifically, targeting KEAP1 in combination with oxidative PPP enzymes mitigated the deleterious effects of these knockouts on growth rates. These results demonstrate how our integrated framework, combining genetic, transcriptomic, and flux measurements, can improve elucidation of metabolic network alterations, and guide precision targeting of metabolic vulnerabilities based on tumor genetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“This reprogramming of cellular metabolism is now considered an essential hallmark of tumorigenesis (Pavlova and Thompson, 2016).”
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“We also note the critical importance of sgRNA efficacy and anticipate that continued improvements in sgRNA design (Chari et al., 2015; Doench et al., 2016; Erard et al., 2017) will be critical to improving consistency and signal to noise in the assays.”
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960 · cited 2×
“15, we observed 35 interactions (Z score < 3) in the combined HeLa and A549 interaction network (Figure S2B; Table S4), of which 10 ( 30%) have been previously reported as protein-protein interactions (Stark et al., 2006).”
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · cited 1×
“In this regard, the advent of CRISPR screening technology now provides a rapid, high-throughput means to functionally characterize large gene sets (Shalem et al., 2014; Wang et al., 2014).”
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 1×
“This metabolic rewiring is coordinated, in part, by the selective expression of distinct isozymes, which may benefit the cell by offering different kinetics or modes of regulation (Chaneton et al., 2012; Christofk et al., 2008; Patra et al., 2013).”
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 2×
“DISCUSSION While it is clear that cancer cells rely on aerobic glycolysis to maintain biosynthetic fluxes and ATP demands (Hsu and Sabatini, 2008), how the underlying metabolic network topology changes in response to specific oncogenic events is not fully clear.”
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 1×
“KEAP1 is a redox-sensitive E3 ubiquitin ligase that targets oxidized NRF2, the master transcriptional regulator of the cellular antioxidant response (DeNicola et al., 2011; Ishii et al., 2000; Thimmulappa et al., 2002), and previous work has demonstrated an ability of NRF2 to alter metabolic fluxes…”
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617 · cited 1×
“This analysis has led to greater annotation of essential genes in human cancers and context-dependent dispensability (Hart et al., 2015; Wang et al., 2015).”
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 1×
“Ectopic expression of WT KEAP1 decreased NRF2 stabilization as compared to constitutively active C273S mutant KEAP1 (Zhang and Hannink, 2003) (Figure S4B).”
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 2×
“…the master transcriptional regulator of the cellular antioxidant response (DeNicola et al., 2011; Ishii et al., 2000; Thimmulappa et al., 2002), and previous work has demonstrated an ability of NRF2 to alter metabolic fluxes (DeNicola et al., 2015; Mitsuishi et al., 2012; Thimmulappa et al., 2006).”
Birsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388
Metabolic heterogeneity in human lung tumors
Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.034 · Cited by 1,138 · cited 1×
“For instance, a unique metabolic feature of tumor cells is a reliance on aerobic glycolysis to satisfy biosynthetic and ATP demands (Hensley et al., 2016).”
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“Loss-of-function mutation of KEAP1 is observed in 20%–50% of NSCLCs (Singh et al., 2006).”
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
Thimmulappa, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25790 · Cited by 1,028 · cited 2×
“…the master transcriptional regulator of the cellular antioxidant response (DeNicola et al., 2011; Ishii et al., 2000; Thimmulappa et al., 2002), and previous work has demonstrated an ability of NRF2 to alter metabolic fluxes (DeNicola et al., 2015; Mitsuishi et al., 2012; Thimmulappa et al., 2006).”
PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update
Wang, X., Spandidos, A., Wang, H., & Seed, B. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1013 · Cited by 720
Serine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661 · cited 1×
“This metabolic rewiring is coordinated, in part, by the selective expression of distinct isozymes, which may benefit the cell by offering different kinetics or modes of regulation (Chaneton et al., 2012; Christofk et al., 2008; Patra et al., 2013).”
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652 · cited 2×
“Consistent with our findings, KEAP1 mutation increases intracellular GSH levels and need for cysteine, causing an increased need for glutamine anaplerosis to support glutamate/cysteine antiporter flux (SLC7A11) (Muir et al., 2017; Romero et al., 2017).”
BackgroundTracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells
Lewis, C. A., Parker, S. J., Fiske, B. P., McCloskey, D., Gui, D. Y., Green, C. R., Vokes, N. I., Feist, A. M., Vander Heiden, M. G., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.008 · Cited by 562
Self-citationCombinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions
Shen, J. P., Zhao, D., Sasik, R., Luebeck, J., Birmingham, A., Bojorquez-Gomez, A., Licon, K., Klepper, K., Pekin, D., Beckett, A. N., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4225 · Cited by 359 · cited 7×
“The dual-gRNA library was generated as previously described (Figure S1A) (Shen et al., 2017).”
InfluentialSelf-citationPassenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339 · cited 3×
“, ENO1 and ENO3) and consistent with previously described mechanisms of metabolic synthetic lethality (Dey et al., 2017; Muller et al., 2012).”
Muir, A., Danai, L. V., Gui, D. Y., Waingarten, C. Y., Lewis, C. A., & Vander Heiden, M. G. (2017) · eLife · doi:10.7554/elife.27713 · Cited by 311 · cited 1×
“Consistent with our findings, KEAP1 mutation increases intracellular GSH levels and need for cysteine, causing an increased need for glutamine anaplerosis to support glutamate/cysteine antiporter flux (SLC7A11) (Muir et al., 2017; Romero et al., 2017).”
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264 · cited 2×
“, ENO1 and ENO3) and consistent with previously described mechanisms of metabolic synthetic lethality (Dey et al., 2017; Muller et al., 2012).”
Self-citationKEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160 · cited 1×
“Other recent work has also implicated KEAP1 mutational status as a driver of chemotherapeutic resistance in preclinical models of lung cancer and further demonstrates the need for new paradigms connecting oncogenicmutations to cancer cell survival (Krall et al., 2017).”
Cited by
The pentose phosphate pathway in health and disease
TeSlaa, T., Ralser, M., Fan, J., & Rabinowitz, J. D. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00863-2 · Cited by 650
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Gonatopoulos-Pournatzis, T., Aregger, M., Brown, K. R., Farhangmehr, S., Braunschweig, U., Ward, H. N., Ha, K. C. H., Weiss, A., Billmann, M., Durbic, T., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0437-z · Cited by 142
Metabolic regulation of somatic stem cells in vivo
Meacham, C. E., DeVilbiss, A. W., & Morrison, S. J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00462-1 · Cited by 85
Functional genomics and the future of iPSCs in disease modeling
Brooks, I. R., Garrone, C. M., Kerins, C., Kiar, C. S., Syntaka, S., Xu, J. Z., Spagnoli, F. M., & Watt, F. M. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.019 · Cited by 54
Metadata
- Authors
- Zhao, D., Badur, M. G., Luebeck, J., Magaña, J. H., Birmingham, A., Sasik, R., Ahn, C. S., Ideker, T., Metallo, C. M., & Mali, P.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 69
- Issue
- 4
- Pages
- 699-708.e7
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2786246553
- Cited by
- 95
- References
- 26
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.